News
Phase II study of erlotinib (E) combined with fixed dose-rate gemcitabine (FDR-Gem) as first-line treatment for advanced adenocarcinoma of the pancreas (PDAC). Background: The role of F-18 FDG-PET/CT ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback